Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 8/20 | 0.58 |
| ▸ | UMPS | P11172 | 4/20 | 0.58 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12144307 | 1.00 | P2RY2 (0.58) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL2130675 | 0.85 | P2RY2 (0.61) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL12727821 | 0.85 | P2RY2 (0.61) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL1364786 | 0.84 | UMPS (0.65) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL15196242 | 0.84 | P2RY2 (0.63) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL1363428 | 0.84 | P2RY2 (0.63) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL15522444 | 0.84 | P2RY2 (0.63) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL12143538 | 0.84 | UMPS (0.65) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL12143119 | 0.84 | UMPS (0.65) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL9397237 | 0.84 | P2RY2 (0.60) | P2RY2UMPSDNPH1P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | claimed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | claimed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | P2RY2 1891/4885UMPS 17/4885DNPH1 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.